Yonemori, Kan

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial

Subbiah, V., Kreitman, R. J., Wainberg, Z. A., Gazzah, A., Lassen, U., Stein, A., Wen, P. Y., Dietrich, S., de Jonge, M. J. A., Blay, J.-Y., et al. (2023) · Nature Medicine

Melanoma and MAPK PathwaysGastrointestinal Tumor Research and Treatment

Cited by 343

Prognostic factors and clinical outcomes in patients with leptomeningeal metastasis from solid tumors.

Waki, F., Ando, M., Takashima, A., Yonemori, K., Nokihara, H., Miyake, M., Tateishi, U., Tsuta, K., Shimada, Y., Fujiwara, Y., et al. (2009) · Journal of Neuro-Oncology

Brain Metastases and TreatmentManagement of metastatic bone disease

Cited by 145

Feasibility and usefulness of the ‘Distress Screening Program in Ambulatory Care’ in clinical oncology practice

Shimizu, K., Ishibashi, Y., Umezawa, S., Izumi, H., Akizuki, N., Ogawa, A., Fujiwara, Y., Ando, M., Katsumata, N., Tamura, K., et al. (2010) · Psycho-Oncology

Cancer survivorship and carePalliative and Oncologic Care

Cited by 70